Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 3/20 | 0.53 |
| ▸ | PRKACA | P17612 | 2/20 | 0.53 |
| ▸ | PRKX | P51817 | 2/20 | 0.53 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.53 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | GSK3A | P49840 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.53 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | GRK5 | P34947 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | DHODH | Q02127 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 2/20 | 0.47 |
| ▸ | F10 | P00742 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4717082 | 0.88 | KMT2A (0.53) | ROCK2PRKACAPRKXPRKCQROCK1 | |
| SCHEMBL4720513 | 0.87 | L3MBTL1 (0.53) | ROCK2PRKACAPRKXPRKCQROCK1 | |
| SCHEMBL5615873 | 0.85 | MMP13 (0.51) | ROCK2PRKACAPRKXPRKCQROCK1 | |
| SCHEMBL4719433 | 0.85 | MMP13 (0.51) | ROCK2PRKACAPRKXPRKCQROCK1 | |
| SCHEMBL5616125 | 0.84 | MMP13 (0.50) | ROCK2PRKACAPRKXPRKCQROCK1 | |
| SCHEMBL4715297 | 0.84 | ROCK2 (0.71) | ROCK2PRKACAPRKXPRKCQROCK1 | |
| SCHEMBL8348717 | 0.83 | ROCK1 (0.65) | ROCK2PRKACAPRKXPRKCQROCK1 | |
| SCHEMBL14602326 | 0.83 | DRD2 (0.49) | ROCK2PRKACAPRKXPRKCQROCK1 | |
| SCHEMBL5615674 | 0.82 | MMP13 (0.47) | ROCK2PRKACAPRKXPRKCQROCK1 | |
| SCHEMBL3237840 | 0.81 | NAMPT (0.58) | ROCK2PRKACAPRKXPRKCQROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166609-B2 | Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-01-23 | — | — | US | claimed |
| US-20040167120-A1 | Novel Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-08-26 | — | — | US | claimed |
| US-7166609-B2 | Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-01-23 | — | — | US | disclosed |
| US-7166609-B2 | Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-01-23 | — | — | US | disclosed |
| US-7166609-B2 | Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167120-A1 | Novel Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases | MMP13, DPYD, MMP1 | ROCK2 3577/4885PRKACA 2824/4885PRKX 3387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.